MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation

Francis J. Giles, Jorge Cortes, Dan Jones, Donald Bergstrom, Hagop Kantarjian, Steven J. Freedman

Research output: Contribution to journalArticlepeer-review

340 Scopus citations

Fingerprint

Dive into the research topics of 'MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds